PLXP PLx Pharma Inc

On March 16, 2021, PLx Pharma Inc. (the “Company”) completed a closing of an exercise of the underwriters’ option to purchase an additional 1,049,700 shares of common stock at the public offering price of $8.00 per share as part of the firm commitment underwritten offering that initially closed on March 5, 2021, resulting in additional net proceeds to the Company of approximately $7.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. After giving effect to this exercise of the over-allotment option, the total number of shares sold by Company in the public offering increased to 8,924,700 shares and net proceeds increased to approximately $66.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. acted as the joint book-running managers for the public offering. The shares were offered by the Company pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-230478) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on April 4, 2019. A prospectus supplement relating to, and describing the terms of, the offering was previously filed with the SEC on March 4, 2021 and is available on the SEC’s website at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering can also be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863 or by e-mail at prospectus@raymondjames.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.